Silodosin in the treatment of benign prostatic hyperplasia
Maxime Rossi, Thierry Roumeguère
Department of Urology, Erasme Hospital, University Clinics of Brussels, ULB, Brussels, Belgium
Abstract: Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with extensions out to five years. These agents have been shown to prevent symptomatic progression of the disease. The aim of this article is to offer a critical review of the current literature on silodosin, formerly known as KMD-3213, a novel alpha-blocker with unprecedented selectivity for a1A-adrenergic receptors, as compared with both a1B- and a1D -adrenoceptors, exceeding the selectivity of all currently used a1-blockers, and with clinically promising effects.
Keywords: silodosin, a1A- blockers, lower urinary tract symptoms, benign prostatic hyperplasia, uroselectivity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]